Neonatal screening for congenital adrenal hyperplasia

European Journal of Endocrinology, Supplement

Volumn 151, Issue 3, 2004, Pages

  Van Der Kamp, Hetty J ^a   Wit, Jan M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROGESTERONE;

BIRTH WEIGHT; CONFERENCE PAPER; CONGENITAL ADRENAL HYPERPLASIA; DEATH; DEHYDRATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HISTORY OF MEDICINE; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; NEWBORN SCREENING; PREVALENCE; SALT LOSING NEPHRITIS; VALIDATION PROCESS;

17-ALPHA-HYDROXYPROGESTERONE; ADRENAL HYPERPLASIA, CONGENITAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT, NEWBORN; NEONATAL SCREENING; PREDICTIVE VALUE OF TESTS; RADIOIMMUNOASSAY;

EID: 10344226651     PISSN: 08044635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Pang S & Shook MK. Current status of neonatal screening for congenital adrenal hyperplasia [see comments]. Current Opinion in Pediatrics 1997 9 419-423.
2. van der Kamp HJ & Stikkelbroeck MML. Development of hyponatremia and hyperkalemia in neonates with congenital adrenal hyperplasia (21-hydroxylase deficiency). Hormone Research 2002 58 (Suppl 2) 1-198.
3. van der Kamp HJ, Noordam K, Elvers B, Van Baarle M, Otten BJ & Verkerk PH. Newborn screening for congenital adrenal hyperplasia in the Netherlands. Pediatrics 2001 108 1320-1324.
4. Wilson JMG & Jungner G. Principles and practice of screening for disease. Public Health Papers No. 34. Geneva: World Health Organization. 1968.
5. Therrell BL. US newborn screening policy: dilemmas for the twenty-first century. Molecular Genetics and Metabolism 2001 74 64-74.
6. Guthrie R & Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963 32 338.
7. Dussault JH. Commentary. The anecdotal history of screening for congenital hypothyroidism. Journal of Clinical Endocrinology and Metabolism 1999 84 4332-4334.
8. Pang S, Hotchkiss J, Drash AL, Levine LS & New MI. Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 1977 45 1003-1008.
9. Pang S, Murphey W, Levine LS, Spence DA, Leon A, La Franchi S, Surve AS & New MI. A pilot newborn screening for congenital adrenal hyperplasia in Alaska. Journal of Clinical Endocrinology and Metabolism 1982 55 413-420.
10. Pang S. International Newborn Screening Collaborative Study on 21-hydroxylase deficiency. Pediatric Research 2003 53 155A-156A.
11. Therrell BL Jr, Berenbaum SA, Manter-Kapanke V, Simmark J, Korman K, Prentice L, Gonzalez J & Gum S. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998 101 583-590.
12. Nass R & Baker S. Learning disabilities in children with congenital adrenal hyperplasia. Journal of Child Neurology 1991 6 306-312.
13. Donaldson MD, Thomas PH, Love JG, Murray GD, McNinch AW & Savage DC. Presentation, acute illness, and learning difficulties in salt wasting 21-hydroxylase deficiency. Archives of Disease in Childhood 1994 70 214-218.
14. Prader A. Der Genitalbefund beim Pseudohermaphroditismus femininus des kongenitalen adrenogenitalen Syndroms. Helvetica Paediatrica Acta 1954 3 231-248.
15. Pang S. Newborn screening for congenital adrenal hyperplasia. Pediatric Annals 2003 32 516-523.
16. van der Kamp HJ. Thesis/Dissertation. 2001.
17. Al Saedi S, Dean H, Dent W, Stockl E & Cronin C. Screening for congenital adrenal hyperplasia: the Delfia Screening Test overestimates serum 17-hydroxyprogesterone in preterm infants. Pediatrics 1996 97 100-102.
18. Naruse H, Suzuki E, Irie M, Tsuji A, Takasugi N, Fukushi M, Matsuura N & Shimozawa K. Neonatal screening for congenital adrenal hyperplasia in Japan. Annals of the New York Academy of Sciences 1985 458 103-110.
19. Thompson R, Seargeant L & Winter JS. Screening for congenital adrenal hyperplasia: distribution of 17 alpha-hydroxyprogesterone concentrations in neonatal blood spot specimens [see comments]. Journal of Pediatrics 1989 114 400-404.
20. Cutfield WS & Webster D. Newborn screening for congenital adrenal hyperplasia in New Zealand. Journal of Pediatrics 1995 126 118-121.
21. Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S & Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. Journal of Pediatrics 1997 130 128-133.
22. Steigert M, Schoenle EJ, Biason-Lauber A & Torresani T. High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland. Journal of Clinical Endocrinology and Metabolism 2002 87 4106-4110.
23. Larsson A, Thil'en A, Hagenfeldt L. Dobeln von U & Guthenberg C. Screening of half a million Swedish newborn infants for congenital adrenal hyperplasia. Screening 1992 1 159-166.
24. Balsamo A, Cacciari E, Piazzi S, Cassio A, Bozza D, Pirazzoli P & Zappella F. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics 1996 98 362-367.
25. Eyskens, F. Screening for inborn errors of metabolism; the experience in the province of Antwerp PhD Thesis University of Antwerp, 1997.
26. Cartigny-Maciejewski M, Guilley N, Vanderbecken S, Gorde S, Stuckers C, Ponte C, Weill J, Farriaux JP & Paux E. Neonatal screening of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Lille experience 1980-1996. Archives of Pediatrics 1999 6 151-158.
27. Stikkelbroeck MML, Van der Kamp HJ & Van Baarle W. Neonatal screening op het adrenogenitaal syndroom. Pilotonderzoek en landelijke invoering 1998-2001. Bithoven: RIVM. 2002.
28. Lanting CI & Verkerk PH. Evaluatie van de screening op AGS/CHT/PKU bij kinderen geboren in 2002. TNO Prevention and Health, Leiden.
29. Nordenstrom A, Thilen A, Hagenfeldt L, Larsson A & Wedell A. Genotyping is a valuable diagnostic complement to neonatal screening for congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency [see comments]. Journal of Clinical Endocrinology and Metabolism 1999 84 1505-1509.
30. Brosnan PG, Brosnan CA, Kemp SF, Domek DB, Jelley OH, Blackett PR & Riley WJ. Effect of newborn screening for congenital adrenal hyperplasia. Archives of Pediatrics and Adolescent Medicine 1999 153 1272-1278.
31. Rohrer TR, Gassmann KF, Pavel ME & Dorr HG. Pitfall of newborn screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Biology of the Neonate 2003 83 65-68.
32. Thil'en A, Nordenstrom A, Hagenfeldt L, Von Dobeln U, Gutherberg C & Larsson A. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. Pediatrics 1998 101 E11.
33. Brosnan CA, Brosnan P, Therrell BL, Slater CH, Swint JM, Anneyers JE & Riley WJ. A comparative cost analysis of newborn screening for classic congenital adrenal hyperplasia in Texas. Public Health Reports 1998 113 170-178.
34. van der Kamp HJ & Koopman HM. Health related quality of life in 2-year-old children with congenital adrenal hyperplasia is not reduced. Hormone Research 2003 60 (Suppl 2) 78.
35. Honour JW. Procedure for neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hormone Research 2001 55 201-205.